Consensus statement to Schering-Plough Pharmaceuticals from the health care community regarding Rebetron development and marketing.
D000998:Antiviral Agents; D002626:Chemistry, Pharmaceutical; D004338:Drug Combinations; D006297:Health Services Accessibility; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha; D007372:Interferons; D010344:Patient Advocacy; D017060:Patient Satisfaction; D012254:Ribavirin; D014481:United States
D000998:Antiviral Agents; D004338:Drug Combinations; D016898:Interferon-alpha; C118689:Rebetron; D012254:Ribavirin; D007372:Interferons